Abstract:Mitophagy, a selective autophagic process, has emerged as a pathway involved in degrading dysfunctional mitochondria. Herein, new platinum(II)-based chemotherapeutics with mitophagy-targeting properties were proposed. Four novel binuclear anticancer Pt(II) complexes with 4′-substituted-2,2′:6′,2′′-terpyridine derivatives (tpy1–tpy4), i.e., [Pt2(tpy1)(DMSO)2Cl4]CH3OH (tpy1Pt), [Pt(tpy2)Cl][Pt(DMSO)Cl3]CH3COCH3 (tpy2Pt), [Pt(tpy3)Cl][Pt(DMSO)Cl3] (tpy3Pt), and [Pt(tpy4)Cl]ClCH3OH (tpy4Pt), were designed and prepared. Moreover, their potential antitumor mechanism was studied. Tpy1Pt–tpy4Pt exhibited more selective cytotoxicity against cisplatin-resistant SK-OV-3/DDP (SKO3cisR) cancer cells compared with those against ovarian SK-OV-3 (SKO3) cancer cells and normal HL-7702 liver (H702) cells. This selective cytotoxicity of Tpy1Pt–tpy4Pt was better than that of its ligands (i.e., tpy1–tpy4), the clinical drug cisplatin, and cis-Pt(DMSO)2Cl2. The results of various experiments indicated that tpy1Pt and tpy2Pt kill SKO3cisR cancer cells via a mitophagy pathway, which involves the disruption of the mitophagy-related protein expression, dissipation of the mitochondrial membrane potential, elevation of the [Ca2+] and reactive oxygen species levels, promotion of mitochondrial DNA damage, and reduction in the adenosine triphosphate and mitochondrial respiratory chain levels. Furthermore, in vivo experiments indicated that the dinuclear anticancer Pt(II) coordination compound (tpy1Pt) has remarkable therapeutic efficiency (ca. 52.4%) and almost no toxicity. Therefore, the new 4′-substituted-2,2′:6′,2′′-terpyridine Pt(II) coordination compound (tpy1Pt) is a potential candidate for next-generation mitophagy-targeting dinuclear Pt(II)-based anticancer drugs.

Synthesis and Antitumor Properties of Temozolomide-Based Platinum(IV) Complexes

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

Advances in the Chemotherapy of Malignant Gliomas with Temozolomide

Mechanism of temozolomide-induced antitumour effects on glioma cells

Dddr-31. The Chemotherapeutic Activity Of Temozolomide Is Antagonized By Its Hydrolysis Product, Aic

Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells

Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy Against Glioblastoma Multiforme.

Temozolomide: a novel oral alkylating agent

Recent Approaches to Improve the Antitumor Efficacy of Temozolomide

Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

Experimental study of interstitial chemotherapy against glioma with sustained-release temozolomide

Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy Against Glioblastoma Multiforme

Synthesis, Characterization, and Antitumor Biological Evaluation of Novel Fluorine‐containing Platinum (IV) Complexes

Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Enhanced Efficacy of Temozolomide Loaded by Tetrahedral Framework DNA Nanoparticle in Therapy for Glioblastoma.

A monofunctional trinuclear platinum complex with steric hindrance demonstrates strong cytotoxicity against tumor cells.

Temozolomide Dosing Regimens for Glioma Patients

Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma

Synthesis and anticancer mechanisms of four novel platinum(II) 4′-substituted-2,2′:6′,2′′-terpyridine complexes

Temozolomide resistance in high grade gliomas